Cooperative Agreement U01CA299401
Award Date
8/1/25
Completion Date
7/31/28
Dollars Obligated
$398K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Cooperative Agreement
Place of Performance
Texas, USA
Similar Awards
This federal Project Grant award of $147,486, awarded on December 1, 2025 by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program), supports research by Baylor College of Medicine to develop a novel "RECON" immune tolerization strategy. The goal is to investigate the trade-offs between oncogene pathogenicity and immunogenicity, which could enable dissection of the genetic and phenotypic alterations governing immune evasion independently of tumorigenesis during...
The National Cancer Institute (NCI), under CFDA 93.396 - Cancer Biology Research, awarded a $449,726 project grant to the University of Illinois to develop tools that enable the rapid analysis of changes in protein interactions within living cells. The project aims to significantly improve the sensitivity and temporal resolution of existing proximity labeling approaches used to map dynamic protein interactomes. Key innovations include engineering biotin ligases that can label proteins with...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will provide $169,932 from September 2024 to July 2029 to The Trustees of Columbia University in the City of New York to advance proteomics technologies for cancer research. The award will enable the recipient's Proteomics and Macromolecular Crystallography Shared Resource to enhance its capabilities by developing innovative methodologies, including automated deep proteomic profiling for...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $872,555 to the Dana-Farber Cancer Institute, Inc. (DFCI) in Boston, MA over a five-year period from September 1, 2024 to August 31, 2029. The award aims to catalyze long-read cancer genome sequencing efforts through the development of informatic methods for the discovery and characterization of somatic genetic alterations in cancer genomes. Key objectives include improving...
This federal Cooperative Agreement award for $811,500.00 from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) supports research to bridge the gap between bioinformatics and mathematical modeling for patient-specific tumor modeling. The project aims to merge bioinformatics software for analyzing single-cell and spatial multi-omics data with an agent-based modeling framework to simulate cell interactions in virtual tumor environments. Key objectives include refining a cell...
This Cooperative Agreement award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $639,882 to the University of North Carolina at Chapel Hill to conduct research aimed at elucidating the molecular mechanisms underlying metastasis organ tropism in breast cancer. The project will utilize a comprehensive dataset of human primary and metastatic tumor samples, as well as genetically engineered mouse models, to identify the molecular determinants driving lung and...
The National Cancer Institute (NCI) awarded a $831,565 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to the University of Massachusetts Medical School (UMass Medical) to develop an Integrative Analysis and Visualization Platform for Cancer Regulatory Genomics. The project aims to create a Regulatory-Element-Target-Gene Atlas that will enable researchers to explore connections between regulatory elements and genes associated with cancer. It will also perform...
This $1,008,000 Cooperative Agreement award was provided by the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (CFDA 47.084) program. The project aims to develop a high-throughput platform for screening millions of T-cell receptors (TCRs) against a large set of clinically relevant cancer antigens, in order to identify and validate promising TCRs for cancer-specific cell killing. The goal is to discover and validate multiple anti-cancer TCRs that could...
The National Cancer Institute (NCI) awarded a $877,856 Cooperative Agreement under the Cancer Biology Research (CFDA 93.396) program to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to develop the Galaxy for Cancer (Galaxy-C) computational workbench. The goal is to create a platform that enables cancer researchers, especially those with limited computational skills, to more easily access, analyze, and extract insights from diverse cancer datasets and analysis tools....
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides funding to support the computational research and platform development activities of a laboratory-based research specialist at the Cleveland Clinic Lerner College of Medicine. The key products and services delivered under this $212,567 award, spanning from September 2024 to August 2029, include: Computational analysis of cancer patient-derived next-generation...